Exhaled 8-isoprostane in sarcoidosis: relation to superoxide anion production by bronchoalveolar lavage cells.
OBJECTIVE
This study was designed to examine the mutual relationship between 8-isoprostane in exhaled breath condensate (EBC) and superoxide anion generation by bronchoalveolar lavage fluid (BALF) cells in patients with sarcoidosis.


METHODS
About 29 patients with sarcoidosis, 34 healthy never smokers (control group for EBC) and 15 healthy never smokers (control group for BAL) were examined. EBC was collected directly before bronchoscopy. 8-Isoprostane was measured by ELISA, and superoxide anion by colorimetry.


RESULTS
Exhaled breath condensate 8-isoprostane is increased in sarcoidosis (median, 25-75 percentile): 2.50; 2.50-3.90 versus 6.20; 2.50-16.95 pg/ml, p ≤ 0.05). Spontaneous superoxide anion release from BALF cells was significantly elevated only in patients with a high percentage of lymphocytes in BALF (6.42 ± 1.24 vs. 23.52 ± 4.30 nmol/10(6) cells, p ≤ 0.01). There were no correlations between 8-isoprostane and spontaneous or stimulated superoxide anion release.


CONCLUSIONS
We confirmed higher concentrations of EBC 8-isoprostane in sarcoidosis and higher spontaneous release of superoxide anion from BALF cells in patients with sarcoidosis. The increase of EBC 8-isoprostane is not directly related to superoxide anion released from BALF cells.
Department of Pneumology and Allergy, Medical University of Lodz, Kopcinskiego Str 22, 90-153, Lodz, Poland. piotrow@toya.net.pl
Wojciech J
WJ
Piotrowski
Zofia
Z
Kurmanowska
Adam
A
Antczak
Jerzy
J
Marczak
Maciej
M
Ciebiada
Paweł
P
Górski
D015415:Biomarkers / Q000378:metabolism; D001944:Breath Tests; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology*; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000378:metabolism; D045853:Exhalation; D006801:Humans; D018384:Oxidative Stress; D012507:Sarcoidosis / Q000378:metabolism* / Q000473:pathology; D013481:Superoxides / Q000378:metabolism*; D014662:Vasoconstrictor Agents / Q000378:metabolism
D015415:Biomarkers; D014662:Vasoconstrictor Agents; D013481:Superoxides; C075750:8-epi-prostaglandin F2alpha; D015237:Dinoprost